We report associations of a novel, multi-protein-derived biomarker of IL-6 activity/bioavailability with several clinical and cognitive outcomes in a sample of individuals with depression including somatic symptoms, fatigue, depression severity, and psychomotor speed. The gene discussed is IL6; the disease is depressive symptom measurement.